Maine is currently home to 200 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Bangor, Portland, Scarborough and Auburn. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NCT04134260
Recruiting
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechani... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Lafayette Family Cancer Center-EMMC, Brewer, Maine
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268
Recruiting
This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: MaineHealth Coastal Cancer Treatment Center, Bath, Maine
Conditions: Intracranial Meningioma, Grade 2 Meningioma
Register for Updates
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy
NCT06543446
Recruiting
The investigators aim to compare the risk of mortality of Non-implantable carioverter defibrillator (ICD) vs. ICD management in patients with heart failure with reduced ejection fraction (HFrEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: MaineHealth, Portland, Maine
Conditions: Heart Failure with Reduced Ejection Fraction
Register for Updates
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05600426
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
05/05/2025
Locations: Maine Health, Scarborough, Maine
Conditions: Severe Aplastic Anemia
Register for Updates
DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)
NCT04709705
Recruiting
A randomized, parallel group, active comparator-controlled trial to evaluate the non-inferiority or superiority of Cryopreserved Platelets with Liquid Stored Platelets in controlling blood loss in patients undergoing Cardiopulmonary Bypass Surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Maine Medical Center, Portland, Maine
Conditions: Cardiac Surgery
Register for Updates
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673
Recruiting
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
05/01/2025
Locations: MaineHealth Maine Medical Center- Scarborough, Scarborough, Maine
Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Register for Updates
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT05563220
Recruiting
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: New England Cancer Specialists, Scarborough, Maine
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347
Recruiting
The purpose of this trial is to generate clinical evidence related to key performance outcomes of Endurant II/IIs Stent Graft Systems verses Gore Excluder / Excluder Conformable AAA Endoprosthesis in subjects with Abdominal Aortic Aneurysms. Subjects are randomized and imaging collected at all follow-up time points to assess the primary endpoint.
Gender:
ALL
Ages:
20 years and above
Trial Updated:
04/29/2025
Locations: Maine Medical Center, Portland, Maine
Conditions: Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Register for Updates
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281
Recruiting
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: Northern Light Eastern Maine Medical Center, Bangor, Maine
Conditions: Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Register for Updates
Standard Versus High Dose ED-Initiated Buprenorphine Induction
NCT06494904
Recruiting
This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post randomization, and opioid withdrawal symptoms, opioid craving, and use of illicit and non-prescribed drugs.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/23/2025
Locations: Maine Medical Center, Portland, Maine
Conditions: Opioid Use Disorder
Register for Updates
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
04/22/2025
Locations: Research Site, Bangor, Maine
Conditions: Acute Coronary Syndrome
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: New England Cancer Specialists, Scarborough, Maine
Conditions: Triple Negative Breast Cancer
Register for Updates